Xoma and Aveo Pharmaceuticals reported a $6-million agreement under which Xoma will manufacture and supply AV-299, Aveo’s anti-HGF antibody, to support early clinical trials. The companies also announced that Xoma has successfully completed the Human Engineering™ (HE™) of AV-299.
For work conducted and licenses granted, Xoma received an upfront license fee and is eligible for development milestones and royalty payments on sales of AV-299. Aveo retains all development and commercialization rights to AV-299.
Under the supply agreement, Xoma will create AV-299 production cell lines and conduct process and assay development, as well as cGMP manufacturing activities in support of Aveo’s IND filing and early clinical trials.
In April, Xoma and Aveo announced an agreement under which Xoma would use its HE technology to humanize AV-299. Xoma created four Human Engineered versions of the original AV-299. From these four versions, Aveo selected one as its lead development candidate.